CIK 0001035354
- Non-accelerated filer
- Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 841368850
- Phone
- +1 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-03-22 | Kariv Tomer Director | Purchase | +2,959 | $8.00 | $24K | 789,878 |
| 2018-03-22 | Kariv Tomer Director | Purchase | +1,600 | $8.00 | $13K | 427,063 |
| 2018-03-22 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +1,441 | $8.00 | $12K | 384,544 |
| 2018-03-22 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +2,959 | $8.00 | $24K | 789,878 |
| 2018-03-22 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +1,600 | $8.00 | $13K | 427,063 |
| 2018-03-21 | Nussbaum Ran Director | Purchase | +1,585 | $7.55 | $12K | 383,103 |
| 2018-03-21 | Nussbaum Ran Director | Purchase | +3,255 | $7.55 | $25K | 786,919 |
| 2018-03-21 | Nussbaum Ran Director | Purchase | +1,760 | $7.55 | $13K | 425,463 |
| 2018-03-21 | Kariv Tomer Director | Purchase | +1,585 | $7.55 | $12K | 383,103 |
| 2018-03-21 | Kariv Tomer Director | Purchase | +3,255 | $7.55 | $25K | 786,919 |
| 2018-03-21 | Kariv Tomer Director | Purchase | +1,760 | $7.55 | $13K | 425,463 |
| 2018-03-21 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +1,585 | $7.55 | $12K | 383,103 |
| 2018-03-21 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +3,255 | $7.55 | $25K | 786,919 |
| 2018-03-21 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +1,760 | $7.55 | $13K | 425,463 |
| 2018-03-21 | Avnur Zafrira Director | Purchase | +263 | $7.60 | $2K | 263 |
| 2018-01-15 | Huertas Pedro Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2017-12-26 | Ward Robert Chief Executive Officer | Grant or award · Restricted Stock Units | −22,427 | 22,427 | ||
| 2017-12-26 | Ward Robert Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | −22,427 | 22,427 | ||
| 2017-12-26 | Ward Robert Chief Executive Officer | Grant or award · Restricted Stock Units | −640,785 | 640,785 | ||
| 2017-12-26 | Ward Robert Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | −640,785 | 640,785 |
Page 16 of 20 · 388 trades